Advertisement

Physiological Modeling and Cancer Risk Assessment

  • Kannan Krishnan
  • Melvin E. Andersen
Part of the NATO ASI Series book series (NSSA, volume 221)

Abstract

Quantitative risk assessment for carcinogens is frequently performed based on evidence of their tumorigenicity in animals. In animal bioassay studies, the test chemicals are administered at high doses and by routes often different from anticipated human exposures. A. particularly challenging aspect in cancer risk assessment is the extrapolation of tumor responses in animals to humans exposed at concentrations much below those tested under the range of the animal bioassay conditions. Since high doses of chemicals are usually administered during these studies, a metabolic saturation may lead to nonlinearities of target tissue dose and exposure concentrations. Tumor response in such cases may not be directly proportional to the external or exposure concentration of the chemical, but rather will reflect the complex nonlinear pharmacokinetic processes occurring in the organism at high concentrations. Therefore, a quantitative understanding of the critical biological determinants of pharmacokinetics and cancer response is necessary to confidently predict the carcinogenic risks associated with human exposure to chemicals. This chapter presents a review of the conventional cancer risk assessment methodology, and discusses the utility of biologically-based tissue dosimetry and cancer response modeling approaches in reducing some of the uncertainties associated with it.

Keywords

Exposure Concentration PBPK Model Physiological Modeling Cancer Risk Assessment Threshold Limit Value 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andersen M.E., 1982. Recent advances in methodology and concepts for characterizing inhalation pharmacokinetic parameters in animals and man. Drug Metab. Rev. 13: 799.Google Scholar
  2. Andersen M.E., Clewell III H.J., Gargas M.L. and Conolly R.B., 1986a. A physiological pharmacokinetic model for hepatic glutathione depletion by inhaled halogenated hydrocarbons. Toxicologist 6: 148.Google Scholar
  3. Andersen M.E., Clewell III H.J., Gargas M.L., MacNaughton M.J., Reitz R.H., Nolan R. and McKenna M., 1991. Physiologically based pharmacokinetic modeling with dichloromethane, its metabolite carbon monoxide and blood carboxyhaemoglobin in rats and humans. Toxicol. Appl. Pharmacol. (in press).Google Scholar
  4. Andersen M.E., Clewell III H.J., Gargas M.L., Smith F.A. and Reitz R.H., 1987 Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. Toxicol. Appl. Pharmacol. 87: 185.PubMedCrossRefGoogle Scholar
  5. Andersen M.E., Gargas M.L., Jones R.A. and Jenkins L.J.Jr, 1980. Determination of the kinetic constants for metabolism of inhaled toxicants in vivo using gas uptake measurements. Toxicol. Appl. Pharmacol. 54: 100.PubMedCrossRefGoogle Scholar
  6. Andersen M.E., Gargas M.L. and Clewell III H.J., 1984. Inhalation pharmacokinetics: evaluating systemic extraction, total metabolism and the time course of induction for inhaled styrène based on steady state blood:gas concentration ratios. Toxicol. Appl. Pharmacol. 73: 176.PubMedCrossRefGoogle Scholar
  7. Andersen M.E., Gargas M.L. and Clewell III H.J., 1986b. Suicide inactivation of microsomal oxidation by cis-and trans-dichloroethylene in male Fischer rats. Toxicologist 6: 148.Google Scholar
  8. Arms A.D. and Travis C.C., 1988. Reference physiological parameters in pharmacokinetic modeling. Office of Health and Environmental Assessment, U.S. EPA, Washington, DC. NTIS PB 88–1906019.Google Scholar
  9. Bischoff K.B., Dedrick R.L., Zakharo D.S. and Longsreth J.A., 1971. Methotrexate pharmacokinetics. J. Pharm. Sci. 60: 1128.PubMedCrossRefGoogle Scholar
  10. Butterworth B. E., 1990. Consideration of both genotoxic and nongenotoxic mechanisms in predicting carcinogenic potential. Mutat. Res. 239: 117.PubMedGoogle Scholar
  11. Casanova M., d’Heck H. and Deyo D.F., 1991. Dichloromethane: metabolism to formaldehyde and formation of DNA-protein crosslinks in mice and hamsters. Toxicologist 11: 180.Google Scholar
  12. Caster W.O., Poncelet J., Simon A.B. and Armstrong W.D., 1956. Tissue weights of the rat. I. Normal values determined by dissection and chemical methods. Proc. Soc. Exp. Biol. Med. 91: 122.PubMedGoogle Scholar
  13. Clewell III H.J. and Andersen M.E., 1987. Dose, species and route extrapolations with a physiologically based model. Drinking Water and Health 8: 159.Google Scholar
  14. Cohen S.M. and Ellwin L.B., 1990. Cell proliferation and cancer. Science 249: 1007.PubMedCrossRefGoogle Scholar
  15. Collins J.M., Dedrick R.L., Flessner M.F. and Longstreth J.A., 1982. Concentration dependent disappearance of fluorouracil from peritoneal fluid in the rat: experimental observations and distributed modeling. J. Pharm. Sci. 71: 735.PubMedCrossRefGoogle Scholar
  16. Conolly R.B., Reitz R.H., Clewell III H.J. and Andersen M.E., 1988. Pharmacokinetics, biochemical mechanism and mutation accumulation: a comprehensive model for chemical carcinogenesis. Toxicol. Lett. 43: 189.PubMedCrossRefGoogle Scholar
  17. Cothern C.R. and Schnare D.W., 1986. The limitation of summary risk management data. Drug Metab. Dispos. 17: 145.Google Scholar
  18. Crump K.S., Hoel D.G., Langley C.H. and Peto R., 1976. Fundamental carcinogenic processes and their implications for low dose risk assessment. Cancer Res. 36: 2973.PubMedGoogle Scholar
  19. Dedrick R.L., Forrester D.D. and Ho D.H.W., 1972. In vitro correlation of drug metabolism — deamination of 1,-B-D-arabinofuransyl cytosine. Biochem. Pharmacol. 21:1.PubMedCrossRefGoogle Scholar
  20. Dourson M.L. and Stara J.F., 1983. History and experimental support of uncertainty (safety) factors. Regul. Toxicol. Pharmacol. 8: 45.Google Scholar
  21. D’Souza R. W., Francis W. R. and Andersen M. E., 1988. Physiological model for tissue glutathione depletion and increased resynthesis after ethylene dichloride exposure. J. Pharmacol. Exp. Ther. 245: 563.PubMedGoogle Scholar
  22. Riser J.G. and Bolt H.M., 1981. Inhalation pharmacokinetics based on gas uptake studies. Arch. Toxicol. 47: 279.CrossRefGoogle Scholar
  23. Fiserova-Bergerova V., 1975. Mathematical modeling of inhalation exposure. J. Combust. Toxicol. 32: 201.Google Scholar
  24. Fishbein L., 1980. New concepts of design and utility of large-scale carcinogenicity studies. J. Toxicol. Environ. Health 6: 1275.PubMedCrossRefGoogle Scholar
  25. Fisher J.W., Whittaker T.A., Taylor D.H., Clewell III J.H. and Andersen M.E., 1990. Physiologically based pharmacokinetic modeling of the pregnant rat: a multiroute exposure model for trichioroethylene and trichloroacetic acid. Toxicol. Appl. Pharmacol. 99: 395.CrossRefGoogle Scholar
  26. Gargas M.L., 1990. An exhaled breath chamber system for assessing rates of metabolism and rates of gastrointestinal absorption with volatile chemicals. J. Amer. Coll. Toxicol. 9: 477.Google Scholar
  27. Gargas M.L. and Andersen M.E., 1989. Determining kinetic constants for chlorinated ethylene metabolism in the rat from rates of exhalation. Toxicol. Appl. Pharmacol. 99: 344.PubMedCrossRefGoogle Scholar
  28. Gargas M.L., Andersen M.E. and Clewell III H.J., 1986a. A physiologically based simulation approach for determining metabolic constants from gas uptake data. Toxicol. Appl. Pharmacol. 86: 341.PubMedCrossRefGoogle Scholar
  29. Gargas M.L., Andersen M.E. and Clewell III H.J., 1986b. Metabolism of inhaled dihalomethanes: differentiation of kinetic constants for two independent pathways. Toxicol. Appl. Pharmacol. 87: 211.CrossRefGoogle Scholar
  30. Gargas M.L., Burgess R.J., Voisard D.E., Cason G.H. and Andersen M.E., 1989. Partition coefficients of low molecular weight volatile liquids and tissues. Toxicol. Appl. Pharmacol. 98: 87.PubMedCrossRefGoogle Scholar
  31. Gaylor D. W., 1979. The EDOL study: Summary and conclusions. J. Environ. Pathol. Toxicol. 3: 179.Google Scholar
  32. Gehring P.J., Watanabe P.G. and Blau G.E., 1976. Pharmacokinetic studies in evaluation of the toxicological and environmental hazard of chemicals. In: “New Concepts in Safety Evaluation” ( M.A. Mehlman, R.E. Shapiro and H. Blumenthal, eds.), page 193. Hemisphere, New York.Google Scholar
  33. Haggard H.W., 1924. The absorption, distribution and elimination of ethyl ether. II. Analysis of the mechanism of the absorption and elimination of such a gas or vapor as ethyl ether. J. Biol. Chem. 59: 753.Google Scholar
  34. Hilderbrand R.L., Andersen M.E. and Jensen jr L.J., 1981. Prediction of in vivo kinetic constants for metabolism of inhaled vapors from kinetic constants measured in vitro. Fundam. Appl. Pharmacol. 1: 403.CrossRefGoogle Scholar
  35. Houk V.N., 1989. The risk of risk assessment. Regul. Toxicol. Pharmacol. 9: 257.PubMedCrossRefGoogle Scholar
  36. Howe R.B., 1983. GLOBAL83: An experimental prograrn developed for the U.S. Environmental Protection Agency as an update to GLOBAL82. OSHA Contract No. 41USC252C3.Google Scholar
  37. Howe R.B. and Crump K.S., 1982. GLOBAL83: a computer program to extrapolate quantal animal toxicity data to low doses (May 1982). OSHA Contract No. 41USC252C3.Google Scholar
  38. Igari Y., Sugiyama Y., Sawada Y., Iga Y. and Hanano M., 1983. Prediction of diazepam disposition in rat and man by a physiologically based pharmacokinetic model. J. Pharmacokinet. Biopharmaceut. 11: 577.CrossRefGoogle Scholar
  39. International Commission on Radiation Protection, 1975. Report of the task group on reference man. ICRP Publication No 23, Pergamon, New York.Google Scholar
  40. Jepson G.W., 1986. A kinetic model for acetylcholinesterase inhibition by diisopropylfluorophosphate in crude rat brain homogenate. Master’s thesis, Wright State University, Dayton, OH.Google Scholar
  41. Kety S.S., 1951. The theory and application of the exchange of the inert gas at the lungs. Pharmacol. Rev. 3: 1.PubMedGoogle Scholar
  42. Kubic V.L., Anders M.W., Engel R.R., Barlow C.H. and Caughey W.S., 1974. Metabolism of dihalomethanes to carbon monoxide. I. Studies. Drug Metab. Dispos. 2: 53.Google Scholar
  43. Leung H.W., Paustenbach D.J., Murray F.J. and Andersen M.E., 1990. A physiologically based pharmacokinetic description and enzyme inducing properties of 2,3,7,8-tetrachlorodibenzo-p-dioxin in the rat. Toxicol. Appl. Pharmacol. 103: 411.PubMedCrossRefGoogle Scholar
  44. Levy G., 1968. Dose dependent effects in pharmacoldnetics. In: “Importance of Fundamental Principles in Drug Evaluation” ( D.H. Tedeschi and R.E. Tedeschi, eds), page 141. Raven, New York.Google Scholar
  45. Lin J.H., Sugiyama Y., Awaza S. and Hanano M., 1982. In vitro and evaluation of the tissue to blood partition coefficient for physiological pharmacoldnetic models. J. Pharmacokinet. Biopharmaceut. 10: 637.CrossRefGoogle Scholar
  46. Lorenz J., Glatt H.R., Fleischmann R., Ferlinz R. and Oesch F., 1984. Drug metabolism in man and its relationship to that in three rodent species. Monooxygenase, epoxide hydrolase and glutathione S-transferase activities in subcellular fractions of lung and liver. Biochem. Med. 32: 43.PubMedCrossRefGoogle Scholar
  47. Mapleson W.W., 1963. An electric analog for uptake and elimination in man. Acta Pharmacol. Toxicol. 14: 265.Google Scholar
  48. McDougal J.N., Jepson G.W., Clewell III H.J., MacNaughton M.G. and Andersen M.E., 1986. A physiological pharrnacokinetic model for dermal absorption of vapors in the rat. Toxicol. Appl. Pharmacol. 85: 286.PubMedCrossRefGoogle Scholar
  49. Moolenaar R.J., 1989. Commentary on EPA carcinogenic risk assessment guidelines. Regul. Toxicol. Pharmacol 9: 230.PubMedCrossRefGoogle Scholar
  50. Moolgavkar S.H., Venzon D.J. 1979. Two event models for carcinogenesis: incidence curves for childhood and adult tumors. Math. Biosci. 47: 55.CrossRefGoogle Scholar
  51. Moolgavkar S.H., Leubeck E.G., de Gunst M., Port R.E. and Schwarz M., 1990. Quantitative analysis of enzyme-altered foci in rat carcinogenesis experiments. I. Single agent regimen. Carcinogenesis 11: 1271.PubMedCrossRefGoogle Scholar
  52. National Academy of Sciences, 1983. Risk assessment in federal government: managing the process. National Academy Press, Washington, DC.Google Scholar
  53. National Academy of Sciences, 1987. Pharmacokinetics in risk assessment. National Academy Press, Washington, DC.Google Scholar
  54. National Toxicology Program, 1985. NTP Technical Report on the toxicology and carcinogenesis studies of dichloromethane in F-344 rats and B6C3F1 mice (inhalation studies). NTP TR TR 306.Google Scholar
  55. Pang K.S., Rowland M. and Tozer T.N., 1978. Evaluation of Michaelis-Menton constants of hepatic drug elimination system. Drug Meta. Dispos. 6: 197.Google Scholar
  56. Park C.N., 1989. Mathematical models in quantitative assessment of carcinogenic risk. Regul. Toxicol. Pharmacol. 9: 236.PubMedCrossRefGoogle Scholar
  57. Ramsey J.C. and Andersen M.E., 1984. A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans. Toxicol. Appl. Pharmacol. 73: 159.PubMedCrossRefGoogle Scholar
  58. Rane A., Wilkinson G.R. and Shand D.G., 1977. Prediction of hepatic extraction ratio from in vitro measurements of intrinsic clearance. J. Pharmacol. Exp. Ther. 200: 420.PubMedGoogle Scholar
  59. Reitz R.H., Mendrela A.L., Park C.N., Andersen M.E. and Guengerich F.P., 1988. Incorporation of in vitro enzyme data into the physiologically based pharmacokinetic model for methylene chloride: implications for risk assessment. Toxicol. Lett. 43: 97.PubMedCrossRefGoogle Scholar
  60. Reitz R.H., Smith F.A. and Andersen M.E., 1986. Metabolism of 14C-methylene chloride. Toxicologist 6: 260.Google Scholar
  61. Riggs D.S., 1963. The mathematical approach to physiological problems: a critical primer. MIT Press, Cambridge, MA.Google Scholar
  62. Sato A. and Nakajima T., 1979a. Partition coefficients of some aromatic hydrocarbons and ketones in water, blood and oil. Br. J. Ind. Med. 36: 231PubMedGoogle Scholar
  63. Sato A. and Nakajima T., 1979b. A vial equilibration method to evaluate the drug metabolizing enzyme activity for volatile hydrocarbons. Toxicol. Appl. Pharmacol. 47: 41.PubMedCrossRefGoogle Scholar
  64. Sawada Y., Harashima H., Hanano M., Sugiyama Y. and Iga T., 1985. Prediction of the plasma concentration of time courses of various drugs in humans based on data from rats. J. Pharmacobiodyn. 8: 757.PubMedCrossRefGoogle Scholar
  65. Singh D.V., Spitzer H.L. and White P.D., 1985. Addendum to the health risk assessment for dichloromethane. Updated carcinogenicity assessment for dichloromethane. EPA/600/8–82/004F.Google Scholar
  66. Thorslund T.W., Brown C.C. and Charnley G., 1987. Biologically motivated cancer risk models. Risk Anal. 7: 109.PubMedCrossRefGoogle Scholar
  67. Tuey D.B. and Matthews D.H., 1980. Use of physiological compartmental model for the rat to describe the pharmacokinetics of several chlorinated biphenyls in the mouse. Drug Metab. Dispos. 8: 397.Google Scholar
  68. United States Environmental Protection Agency, 1987. Update to the health assessment document and addendum for dichloromethane: pharmacokinetics, mechanism of action and epidemiology. EPA 600/8–87/030A.Google Scholar
  69. United States Environmental Protection Agency, 1989. Interim methods for development of inhaled reference doses. (Office of Research and Development, Office of Health and Environmental Assessment, Environmental Criteria and Assessment Office, EPA Report # EPA/600/8–88/066F, Research Triangel Park, NC.Google Scholar
  70. United States Environmental Protection Agency, 1990. Formaldehyde risk assessment update (External review draft). Office of Toxic Substances, US EPA, Washington, DC.Google Scholar
  71. United States Environmental Protection Agency, 1991. Alpha-2µ-globulin: association with chemically-induced renal toxicity and neoplasia in the mate rat. EPA 62%/3–91. Office of Research and Development, OHEA-ECAO, Cincinnati, OH.Google Scholar
  72. van Ginneken C.A.M. and Russel F.G.M., 1989. Saturable pharmacokinetics in the renal excretion of drugs. Clin. Pharmacokinet. 16: 38.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • Kannan Krishnan
    • 1
  • Melvin E. Andersen
    • 1
  1. 1.Chemical Industry Institute of ToxicologyResearch Triangle ParkUSA

Personalised recommendations